Revenue Breakdown
Composition ()
No data
Revenue Streams
Pacira Biosciences Inc (PCRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is EXPAREL, accounting for 78.6% of total sales, equivalent to $139.90M. Other significant revenue streams include ZILRETTA and iovera. Understanding this composition is critical for investors evaluating how PCRX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Pacira Biosciences Inc maintains a gross margin of 72.26%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.93%, while the net margin is 0.83%. These profitability ratios, combined with a Return on Equity (ROE) of 0.96%, provide a clear picture of how effectively PCRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PCRX competes directly with industry leaders such as ABUS and CTMX. With a market capitalization of $861.62M, it holds a significant position in the sector. When comparing efficiency, PCRX's gross margin of 72.26% stands against ABUS's 100.00% and CTMX's 100.00%. Such benchmarking helps identify whether Pacira Biosciences Inc is trading at a premium or discount relative to its financial performance.
